placebo in the trials, respectively. Across PIONEER I and II, demographic and disease characteristics were similar: most subjects were female (63.8% and 67.8%) and white (76.2% and 83.7%). Similarly, the mean ages of all subjects within each trial were 37.0 and 35.5 years, with each having mean disease duration of 11.5 years; the mean abscess and inflammatory nodule counts were 14.3 and 11.3, respectively.
In both studies, the Patient's Global Assessment of Skin Pain (PGA-SP) was administered daily from screening through week 12; respondents were asked to assess pain ''at its worst'' in the 24 hours before assessment on an 11-point numeric rating scale ( from 0 [no skin pain] to 10 [skin pain as bad as you can imagine]). Daily assessments were aggregated into weekly average scores for each subject on the basis of the 7 daily scores collected just before each study visit (the weekly average was considered missing if there were fewer than 4 diary entries). Table I . Difference between adalimumab and placebo groups by pain response categories among subjects with a baseline PGA-SP at worst score of 3 or higher (PIONEER I and PIONEER II) Baseline pain was scored as 6.0 by those who received adalimumab and 6.0 by those who received placebo in PIONEER I and as 5.7 by those who received adalimumab and 6.2 by those who received placebo in PIONEER II. The proportion of subjects achieving at least a 30% (a ranked secondary trial end point), 40%, or 50% reduction and at least a 1-unit reduction from baseline in the PGA-SP with a baseline score 3 or higher was significantly higher for those who received adalimumab than for those who received placebo at each visit in each study, with the exception of the 30% and 50% thresholds at week 12 in PIONEER I (Table I) [odds ratio, 4.78; P \ .001]). The mean changes from baseline in PGA-SP scores were significantly lower at all time points for the group that received adalimumab every week than for the placebo group across both studies (Table II) , and the proportion of time spent at a 30% or greater improvement of pain was significantly higher in the subjects who received adalimumab than in those who received placebo (41.66% vs 27.11% in PIONEER I [P ¼ .0011] and 50.62% vs 25.34% in PIONEER II [P \ .0001]).
The evidence presented here suggests that in addition to improving the physical findings of HS, 4, 5 adalimumab has a rapid and enduring effect on the severity of HS-related skin pain in that the bulk of change in PGA-SP scores occurred in the first 2 weeks after baseline, with a similar pattern of improvement observed through week 12. Though the longer-term efficacy of adalimumab on HS skin pain and optimal dosing are to be determined, evidence from PIONEER I and II suggests that adalimumab is superior to placebo in relieving HS-related skin pain.
The authors would like to acknowledge Ramon Iovin for providing scientific writing assistance, for which AbbVie provided financial support. Diff, Difference; PGA-SP, Patient's Global Assessment of Skin Pain. *Subjects with baseline numeric rating scale at worst score of 3 or higher (intent-to-treat population for period A and last observation carried forward). y Mean PGA-SP at worst score at study week. z Within-group least square mean change in PGA-SP at worst score from baseline to study week. Between-study groups least square mean difference between study groups' change in PGA-SP at worst score from baseline to study week. AbbVie Inc participated in the interpretation of data, review, and approval of the abstract; all authors contributed to the development of the publication and maintained control over the final content.
Reprints not available from the authors. 2,3 Neuropathic itch is a debilitating form of chronic pruritus that occurs secondary to damage to afferent itch pathways. The clinical characteristics of neuropathic itch have been suggested to include nociceptive symptoms, such as burning, tingling, and stinging. 2 Conversely, inflammatory itch is usually not characterized with other nociceptive complaints. However, a recent large study in patients with atopic dermatitis suggests that there might be an association with pain. 4 Distinctions between neuropathic and inflammatory pruritus help guide the diagnostic workup and the selection of the most efficacious classes of medication. Nociceptive characteristics of neuropathic and inflammatory itch have not been well studied. The purpose of this study was to examine differences in nociceptive characteristics between neuropathic and inflammatory itch.
We used cross-sectional survey data collected from 267 adult patients with chronic pruritus at Temple University (Philadelphia, Pennsylvania) and the University of Miami (Miami, Florida) during 2015-2017. Chronic pruritus was defined by itch lasting[6 weeks. Patients with a single dermatologic diagnosis of atopic dermatitis or psoriasis were classified as inflammatory itch (n ¼ 57), and patients with brachioradial pruritus, notalgia paresthetica, unspecified neuropathic itch, or postherpetic neuralgia were classified as neuropathic itch (n ¼ 44) (Table I) . Survey data on the extent to which nociceptive characteristics corresponded to each patient's pruritus were recorded on a linear scale from zero (not at all) to 4 (to a great extent). Mann-Whitney U tests were performed to determine significance of pruritic characteristics between inflammatory and neuropathic itch groups, with significances set at P \.05.
For inflammatory itch, the average patient age was 48.8 years. The average age of patients in the neuropathic itch group was significantly higher (P \ .001) at 63 years. Compared with the neuropathic group, the inflammatory itch group demonstrated a significantly greater mean for the
